Product Pathways - Chromatin Regulation / Epigenetics
SignalSilence® SET8 siRNA II #13107
|13107S||300 µl (3 nmol)||---||In Stock||---|
|13107||carrier free and custom formulation / quantity||email request|
Already purchased this product? Write a Review.
Western blot analysis of extracts from 293T cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-), SignalSilence® SET8 siRNA I #13067 (+) or SignalSilence® SET8 siRNA II (+), using SET8 (C18B7) Rabbit mAb #2996 (upper) or β-Actin (D6A8) Rabbit mAb #8457 (lower). The SET8 (C18B7) Rabbit mAb, which cross-reacts with an unidentified protein at 50 kDa, confirms silencing of SET8 expression while the β-Actin (D6A8) Rabbit mAb is used as a loading control.
SignalSilence® SET8 siRNA II from Cell Signaling Technology (CST) allows the researcher to specifically inhibit SET8 expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products are rigorously tested in-house and have been shown to reduce protein expression by western analysis.
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions For Use
CST recommends transfection with 100 nM SET8 siRNA II 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.
SET domain-containing lysine methyltransferase 8 (SET8), also known as PR/SET domain-containing protein 7 (PR/SET7), is a member of a family of histone lysine methyltransferases, each of which contains a conserved catalytic SET domain originally identified in Drosophila Su[var]3-9, Enhancer of zeste, and Trithorax proteins (1-3). SET8 is a single-subunit enzyme that mono-methylates histone H4 on Lys20, preferably on nucleosomal substrates (1-3). SET8 protein levels and Histone H4 Lys20 methylation are cell cycle regulated, both increasing in S phase and peaking at G2/M phase (4,5). SET8 interacts with the PCNA protein, associates with sites of active DNA synthesis, and is required for DNA replication and genome stability during S phase (5-7). Inhibition of SET8 using shRNA or siRNA results in arrest of replication forks, induction of double-stranded DNA breaks, and a Chk1-mediated cell-cycle arrest in S and G2/M phases of the cell cycle (6,7). Furthermore, SET8 methylates p53 on Lys382, down regulating the pro-apoptotic and checkpoint activation functions of p53 (8). In response to DNA damage, SET8 expression levels decrease, allowing p53 to activate checkpoints and/or apoptosis (8). Both the methylation of histone H4 Lys20 and p53 appear to be important for the functions of SET8 in S phase.
- Fang, J. et al. (2002) Curr Biol 12, 1086-99.
- Xiao, B. et al. (2005) Genes Dev 19, 1444-54.
- Couture, J.F. et al. (2005) Genes Dev 19, 1455-65.
- Rice, J.C. et al. (2002) Genes Dev 16, 2225-30.
- Huen, M.S. et al. (2008) J Biol Chem 283, 11073-7.
- Tardat, M. et al. (2007) J Cell Biol 179, 1413-26.
- Jørgensen, S. et al. (2007) J Cell Biol 179, 1337-45.
- Shi, X. et al. (2007) Mol Cell 27, 636-46.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
CST™ is a trademark of Cell Signaling Technology, Inc.
SignalSilence® is a trademark of Cell Signaling Technology, Inc.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.